ライフサイエンスコーパス: enteric coat

1 The belief that enteric-coated and buffered varieties are less likely to

2 (Pharmacodynamic Evaluation of PL2200 Versus Enteric-Coated and Immediate Release Aspirin in Diabetic

3 The relative risks of UGIB for plain, enteric-coated, and buffered aspirin at average daily do

4 Exposure of mice to enteric-coated antigen promotes an extensive T helper 2-

5 They received enteric-coated ASA after ulcer healing.

6 if still resistant were exposed to low-dose enteric coated aspirin (81 mg) and clopidogrel (75 mg) f

7 parent resistance to a single dose of 325-mg enteric coated aspirin (up to 49%) but not to immediate

8 gle oral dose of 325-mg immediate release or enteric coated aspirin.

9 lowing 7-day regimens in a crossover design: enteric-coated aspirin 100 mg twice daily, enteric-coate

10 : enteric-coated aspirin 100 mg twice daily, enteric-coated aspirin 200 mg once daily, or plain aspir

11 endoscopy were assigned randomly to placebo, enteric-coated aspirin 81 mg/day, rofecoxib 25 mg combin

12 in; there were insufficient data to evaluate enteric-coated aspirin at this dose level.

13 re ibuprofen (400 mg three times a day); and enteric-coated aspirin two hours before delayed-release

14 d the same medications in the reverse order; enteric-coated aspirin two hours before ibuprofen (400 m

15 ized mice with oral allergen, in the form of enteric-coated beads, resulted in marked allergen-specif

16 yed and reduced drug absorption, complicates enteric coated but not immediate release aspirin adminis

17 Oral delivery of devices in enteric coated capsules resulted in significant bioavail

18 irectly into the intestine of cats by use of enteric-coated capsules.

19 nd ritonavir for 7 days, (B) zidovudine plus enteric-coated didanosine for 30 days, or (C) regimen 1

20 and postpartum regimens: (A) zidovudine plus enteric-coated didanosine plus lopinavir and ritonavir f

21 phous solid-state form, and the integrity of enteric-coated drug delivery systems.

22 lipid-based aspirin), and a delayed-release enteric-coated (EC) aspirin.

23 We aimed to establish in vivo evidence that enteric-coated (EC) calcium is bioavailable in pregnant

24 duce the gastrointestinal effects of MMF, an enteric-coated formulation of the drug was developed, ba

25 ed in conjunction with Raman mapping to show enteric coating integrity and observe the distribution o

26 IL-11 was administered daily by enteric, coated multiparticle pellets over the course of

27 Conversion from SRL to enteric coated mycophenolate sodium led to an increase i

28 rospective trial with conversion from SRL to enteric coated mycophenolate sodium.

29 ity to absorb cyclosporin, tacrolimus (Tac), enteric-coated mycophenolate sodium (EC-MPS) and sirolim

30 mplaints from mycophenolate mofetil (MMF) to enteric-coated mycophenolate sodium (EC-MPS) has not bee

31 nversion from mycophenolate mofetil (MMF) to enteric-coated mycophenolate sodium (EC-MPS) in terms of

32 nversion from mycophenolate mofetil (MMF) to enteric-coated mycophenolate sodium (EC-MPS) significant

33 long-term outcomes of patients who received enteric-coated mycophenolate sodium (EC-MPS) versus myco

34 (GI) complications in patients treated with enteric-coated mycophenolate sodium (EC-MPS) versus myco

35 It was of interest to compare enteric-coated mycophenolate sodium (EC-MPS) versus myco

36 Although enteric-coated mycophenolate sodium (EC-MPS) was develop

37 nsisting of reduced tacrolimus dosing (rTd), enteric-coated mycophenolate sodium (EC-MPS), and early

38 In this study, the IEM was combined to enteric-coated mycophenolate sodium (ECMPS).

39 olate mofetil (group A, n=75) versus 1.440 g enteric-coated mycophenolate sodium (group B, n=75), wit

40 first long-term, randomized trial comparing enteric-coated mycophenolate sodium versus mycophenolate

41 l equivalents) was significantly higher with enteric-coated mycophenolate sodium versus mycophenolate

42 observe the distribution of API beneath the enteric-coating on the sucrose spheres.

43 Use of low doses of enteric-coated or buffered aspirin carries a three-fold

44 Once daily 100 mg aspirin (enteric coated) or placebo.

45 approach to characterize the quality of the enteric-coated peptide product.

46 ers ingested either a placebo or a partially enteric-coated preparation of bovine immunoglobulins wit

47 A pH-sensitive enteric coating substantially reduced calcium absorption

48 ) and an oral formulation of this API within enteric-coated sucrose spheres.

49 anules microencapsulated with a pH-sensitive enteric coating to delay intestinal release.

50 replication-deficient, orally administered, enteric-coated, vaccinia virus-vectored vaccine might sa